Kesios Gets Funding To Explore Novel Multiple Myeloma Pathway
This article was originally published in Scrip
Executive Summary
British biotech start-up Kesios Therapeutics Ltd aims to use funds from its £19m ($28.5m) Series A financing, completed Dec. 2, to place its lead candidate drug KES-0001 in clinical studies as a potential treatment for multiple myeloma.